Authors
Latest:
How to Overcome Inertia and Adopt Omnichannel Marketing for PharmaOmnichannel marketing touts delivering efforts across all channels simultaneously, and looks to dethrone the incumbent multichannel marketing, but making the switch isn't exactly easy.
Latest:
Reimagining Medical Education for the Digital AgeEmbracing new digital-based tools is critical throughout the healthcare landscape to prepare for the rise of telemedicine as a permanent way of life.
Latest:
Bottom of the Funnel Conversion though EHR Marketing and its Role in an Omnichannel StrategyWebinar Date/Time: Wed, Dec 7, 2022 2:00 PM EST
Latest:
If Content Is King, Context Is the Power Behind the ThroneNew mediums of technology must be utilized correctly to reap full benefits.
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
Integrating Payers Into Your Digital Communication PlanAn evolving system requires a focus on digital channels
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
Pharma’s Cold Calling: CGT Space at a Critical CrossroadsAs the overall industry pipeline of allogeneic T-cell therapies expands, the onus on manufacturers and their partners to adeptly manage the complex cryogenic logistics process intensifies.
Latest:
Opening Digital Doors: Remote Selling During COVID-19Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.
Latest:
How False Starts Continue to Undermine Omnichannel EffortsOmnichannel marketing bridges the gap from marketing operations to sales excellence. A well-planned, omnichannel marketing strategy allows pharma companies to reach the right people, at the right time, with the right message. Omnichannel marketing provides a holistic view of the customer to improve stakeholder experience across all touchpoints.
Latest:
Addressing the Knowledge Gap in Biologics & Biosimilars: Is a Board Certified Biologics and Biosimilars Program the Answer?Life sciences professionals will need to keep up with market demand for biologics and biosimilars.
Latest:
Strategic Market Access Ensures the Right Treatments at the Right TimeA robust market access strategy ensures that pharmaceutical products, including those with limited distribution, reach patients and are covered by diverse healthcare systems.
Latest:
Breaking OrbitHow pharmaceutical leaders at established companies can still disrupt the status quo and change the game.
Latest:
The Impact of Accelerated Drug DevelopmentDr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.
Latest:
What the Leaders of the Most Effective Teams KnowFindings from hundreds of interviews of exceptional pharma leaders around the world.
Latest:
Ask a Better Question, Make a Better Decision.Harnessing the power of curiosity to position your next big idea
Latest:
Biopharma Must Transform its Payer Launch PlaybookThe profitability of biopharma drug launches in the US will remain in decline until manufacturers reimagine their approach with payers
Latest:
Uncovering the Potential of Advanced Analytics in International Price ManagementHow can pharmaceutical companies successfully apply advanced analytics? Pricing experts from Simon-Kucher & Partners identify the hurdles and winning approaches.
Latest:
China 2021 National Reimbursement Drug List OutlookThe 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Latest:
Clues on Equity Engagement LevelsA survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.
Latest:
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a CatchValue-based price for access (VBPA) may increase access of specialty drugs for patients.
Latest:
AI in Pharma: Where, When, and How Executives are Considering itAs skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.
Latest:
Manage Risk Effectively to Improve the Value of Your AllianceIn this article, Eli Lilly & Co. examines risk management in the context of partnerships with other companies.
Latest:
The Benefits of Enhancing Adverse Event Intake With Case Collection SystemsAutomated risk management and improved regulatory compliance among opportunities offered by case collection.
Latest:
COVID and AMR: Crisis Reframes Antibiotics FightThe redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.
Latest:
Solving One of the Hardest Questions in Cancer: How Do We Ensure Patient Access to Medicines?Pharmaceutical companies are facing new guidelines, laws, and regulations requiring a reconsideration of how to prioritize, develop, commercialize, and ultimately, secure access to medicines.
Latest:
Learning and Development Is the Key to Compliance in Life SciencesEmployees must be able to retain information and remain engaged to keep pace with highly regulated industry.
